Compare Delta Air Lines, Inc. (DAL) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs TransMedics Group Inc — how do they compare? Delta Air Lines, Inc. trades at $89.61 (market cap $59.46B), while TransMedics Group Inc trades at $87.23 (market cap $3.10B). The key difference: Delta Air Lines, Inc. is far larger — about 19.2× TransMedics Group Inc's market cap, and Delta Air Lines, Inc. pays a 0.86% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| DAL | TMDX | |
|---|---|---|
Market Cap | $59.46B | $3.10B |
Sector | Industrials | Technology |
52-Week High | $93.66 | $150.42 |
52-Week Low | $55.65 | $61.99 |
Enterprise Value | $74.77B | $3.49B |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $89.21, down 2.33% on the day, amid strong fundamental performance with three consecutive quarterly earnings beats. The stock maintains attractive valuation metrics including a P/E of 14.99 and P/S of 0.87, while showing robust profitability with 20.12% ROE. Technical indicators suggest a bullish trend with current price near key support at $89. Recent corporate developments include dividend payments and strong cash flow generation of $1.08 billion in 2025.
DAL presents a compelling investment case with strong analyst support (82% buy ratings) and a $108.27 consensus price target implying 21% upside. The airline benefits from premium travel demand and lucrative loyalty partnerships, though faces headwinds from fuel cost volatility and competitive pressures. Earnings momentum remains positive with Q3 2026 expectations of $2.19 EPS.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
